Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Black Diamond Therapeutics, Inc. (BDTX)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Black Diamond Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Black Diamond Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is BDTX. The reporting company's CIK number is 1701541.
The total value of stock buying since 2005 is $75,856,968.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2020-02-03||Versant Vantage I, L.p. (10% Owner)||Buy||894,736||19.00||16,999,984|
|2020-02-03||Hatzis-schoch Brent (See Remarks)||Buy||3,000||19.00||57,000|
|2020-02-03||Shah Rajeev M. (Director)||Buy||1,000,000||19.00||19,000,000|
|2020-02-03||Behbahani Ali (Director)||Buy||800,000||19.00||15,200,000|
|2020-02-03||Bolzon Bradley J Phd (Director)||Buy||894,736||19.00||16,999,984|
|2020-02-03||Deerfield Partners, L.p.||Buy||400,000||19.00||7,600,000|
Insider trading activities including stock purchases, stock sales, and option exercises of BDTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Black Diamond Therapeutics, Inc. (symbol BDTX, CIK number 1701541) see the Securities and Exchange Commission (SEC) website.